LOW AGGREGATE ANTI CD20 LIGAND FORMULATION

• 1. 用于治疗血液学癌症的抗-CD20抗体、PI 3激酶-δ抑制剂以及抗-PD-1或抗-PD-L1抗体的组合 [P] . 中国专利： CN110191720A . 2019-08-30
• 2. 抗CD20抗体与Bcl-2抑制剂和MDM2抑制剂的组合疗法 [P] . 中国专利： CN107847600B . 2021.09.03
• 3. ANTI-CD20 ANTIBODY FORMULATION AND USE OF ANTI-CD20 ANTIBODY FOR TREATMENT OF CD20 POSITIVE DISEASES [P] . WO2021068971A1 . 2021-04-15

  机译： 抗CD20抗体配制和使用抗CD20抗体治疗CD20阳性疾病

• 4. Anti-cd20 antibody formulations and uses thereof in the preparation of a medicament for treating diseases involving cd20 expressing cells [P] . IL202950A . 2014-05-28

  机译： 抗cd20抗体制剂及其在制备用于治疗涉及cd20表达细胞的疾病的药物中的用途

• 5. The formulation of anti-CD20 antibodies, and for the treatment of diseases involving cells that express CD20 in mammals. [P] . CL2008001984A1 . 2009-01-09

  机译： 抗CD20抗体的制剂，用于治疗哺乳动物中表达CD20的细胞的疾病。

• 1. Phase Ⅰ study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma [J] . Lin Gui, Xiaohong Han, Xiaohui He, 中国癌症研究（英文版） . 2016,第002期
• 2. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies. [J] . Liu R, Jiang W, Yang M, Journal of immunotherapy . 2010,第5期
• 3. A phase II II trial evaluating the efficacy of high‐dose high‐dose Radioiodinated Tositumomab ( Anti‐CD20 Anti‐CD20 ) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk high‐risk relapsed or refractory non‐hodgkin non‐hodgkin lymphoma [J] . Chow Victor A., Rajendran Joseph G., Fisher Darrell R., American Journal of Hematology . 2020,第7期
• 4. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. [J] . Stanglmaier M, Faltin M, Ruf P, International Journal of Cancer =: Journal International du Cancer . 2008,第5期
• 5. Convex Formulations of Aggregate Network Air Traffic Flow Optimization Problems [C] . Daniel B. Work, Alexandre M. Bayen IEEE Conference on Decision and Control . 2008
• 6. Role of the immunosuppressive surface ligand CD200 in normal and neoplastic skin [D] . Stumpfova, Magda 2011
• 7. Parkinsonian neurotoxicants impair the anti-inflammatory response induced by IL4 in glial cells: involvement of the CD200-CD200R1 ligand-receptor pair [O] . Neus Rabaneda-Lombarte, Lucas Blasco-Agell, Joan Serratosa, -1
• 8. NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein [O] . Yizhou Zou, Weiguang Luo, Jing Guo, 2018

• 1. 携带全长抗CD20抗体的嵌合型腺病毒Ad5F11b-Anti-CD20载体构建与表达研究 [J] . 杨秋梅 ,吴红平 ,周秀梅 . 浙江理工大学学报 . 2009,第005期
• 2. Anti program death-1/anti program death-ligand 1 in digestive cancers [J] . Eléonore de Guillebon ,Pauline Roussille ,Eric Frouin . 世界胃肠肿瘤学杂志：英文版（电子版） . 2015,第8期
• 3. Influence of Aggregate Grain Size on the Formulation of Sand Concrete in the Construction Industry in Congo [J] . Charlène Bassolokidi Nkengue ,Narcisse Malanda ,Gilbert Ganga . 地质材料（英文） . 2019,第4期
• 4. Structural, Photoluminescent and Theoretical Evidence for Ligand-unsupported Argentophilic Interactions in a Supramolecular Aggregate of Ag_2(Hida)(NH_3)_2 [J] . ZHENG Shao-Liang ,YANG Jin-Hua ,CHEN Xiao-Ming . 结构化学 . 2009,第011期
• 5. 剪切应力诱导血小板聚集与川芎嗪抗聚集作用的实验研究 [C] . 廖福龙 . 中国力学学会现代力学与科技进步学术大会 . 1997
• 6. 抗TNF-α小分子抑制剂的研究及抗CD20Fab-TNFα融合蛋白表达载体的构建、表达和活性的初步测定 [A] . 谷岳 . 2009